Currently, patients with advanced NSCLC harboring “classic” EGFR mutations (Ex19Dels and L858R) usually receive tyrosine kinase inhibitors (TKI) as the standard first-line treatment (5). This evidence concerns the gene EGFR and non-small cell lung carcinoma.